Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: A meta-regression
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084777" target="_blank" >RIV/00023001:_____/24:00084777 - isvavai.cz</a>
Alternative codes found
RIV/68407700:21460/24:00382315 RIV/00216208:11110/24:10478287 RIV/00216208:11120/24:43926720
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S1201971224000572" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1201971224000572</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijid.2024.106986" target="_blank" >10.1016/j.ijid.2024.106986</a>
Alternative languages
Result language
angličtina
Original language name
Understanding the time-driven shifts of vaccine effectiveness against any and severe COVID-19 before and after the surge of Omicron variants within 2.5 years of vaccination: A meta-regression
Original language description
Objectives: The COVID-19 pandemic required rapid development of vaccines within a short period of time which did not allow to assess vaccine effectiveness (VE) in the long-term. Methods: A computerized literature search was undertaken to identify eligible studies, with no language restrictions, published between 1 December 2020 and 30 June 2023. Results: Out of a total of 27,597 publications, 761 studies were included. Early VE of 87.2% decreased to 55.1% after 9 months among populations fully immunized not only with mRNA (proxy mRNA) vaccines, and 66.3% decreased to 23.5% in populations immunized exclusively with non-mRNA vaccines. Protection against severe COVID-19 declined to 80.9% for proxy mRNA vaccines and 67.2% for non-mRNA vaccines. Omicron variants significantly diminished VE. Within 6-8 months of receiving a single booster of an mRNA vaccine, VE declined to 14.0% and 67.7% for any and severe COVID-19, respectively. Multiple mRNA booster doses restored protection that declined to 29.5% and 70.6% for any and severe COVID-19, respectively, within 5-7 months. Conclusion: Outcomes of this meta-regression underscore the evolving nature of COVID-19 in response to vaccination, dosing schedules, and emerging variants, and provide crucial insights for public health interventions and vaccination strategies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30303 - Infectious Diseases
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
International journal of infectious diseases
ISSN
1201-9712
e-ISSN
1878-3511
Volume of the periodical
142
Issue of the periodical within the volume
May 2024
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
"art. no. 106986"
UT code for WoS article
001222282300001
EID of the result in the Scopus database
2-s2.0-85188623635